Privia Health Group, Inc. (NASDAQ:PRVA) Stake Lifted by Swiss National Bank

Swiss National Bank increased its stake in Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,200 shares of the company’s stock after acquiring an additional 7,900 shares during the period. Swiss National Bank’s holdings in Privia Health Group were worth $4,274,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PRVA. Signaturefd LLC bought a new stake in Privia Health Group during the third quarter worth approximately $32,000. Assetmark Inc. boosted its holdings in Privia Health Group by 35.2% during the third quarter. Assetmark Inc. now owns 1,207 shares of the company’s stock worth $41,000 after buying an additional 314 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Privia Health Group during the first quarter worth approximately $47,000. Focused Wealth Management Inc bought a new stake in Privia Health Group during the fourth quarter worth approximately $41,000. Finally, Essex Investment Management Co. LLC bought a new stake in Privia Health Group during the fourth quarter worth approximately $72,000. 66.83% of the stock is currently owned by institutional investors.

Insider Transactions at Privia Health Group

In related news, major shareholder Advisors L.L.C. Mbd sold 24,819,473 shares of the stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $21.61, for a total value of $536,348,811.53. Following the transaction, the insider now directly owns 110,337 shares in the company, valued at $2,384,382.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director William M. Sullivan sold 18,153 shares of the stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $28.57, for a total value of $518,631.21. Following the transaction, the director now directly owns 5,754,318 shares in the company, valued at $164,400,865.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Advisors L.L.C. Mbd sold 24,819,473 shares of the stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $21.61, for a total transaction of $536,348,811.53. Following the completion of the transaction, the insider now owns 110,337 shares in the company, valued at $2,384,382.57. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,371,773 shares of company stock worth $551,840,171. Corporate insiders own 57.60% of the company’s stock.

Privia Health Group Trading Up 0.5 %

Shares of PRVA stock opened at $25.36 on Friday. Privia Health Group, Inc. has a 1 year low of $20.64 and a 1 year high of $44.64. The firm’s 50 day moving average is $26.97 and its 200-day moving average is $25.95. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of 230.55, a PEG ratio of 3.13 and a beta of 0.77.

Privia Health Group (NASDAQ:PRVA – Get Rating) last announced its earnings results on Tuesday, February 28th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.17. Privia Health Group had a net margin of 1.14% and a return on equity of 3.20%. The company had revenue of $364.42 million for the quarter, compared to analyst estimates of $337.16 million. On average, equities research analysts forecast that Privia Health Group, Inc. will post 0.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PRVA shares. Stephens started coverage on shares of Privia Health Group in a research report on Tuesday, April 11th. They issued an “overweight” rating and a $33.00 price target for the company. SVB Securities upped their price target on shares of Privia Health Group from $39.00 to $40.00 in a research report on Friday, May 5th. Royal Bank of Canada started coverage on shares of Privia Health Group in a research report on Thursday, March 9th. They issued an “outperform” rating and a $36.00 price target for the company. The Goldman Sachs Group started coverage on shares of Privia Health Group in a research report on Friday, February 3rd. They issued a “buy” rating and a $32.00 price target for the company. Finally, Credit Suisse Group restated an “outperform” rating and issued a $41.00 price target on shares of Privia Health Group in a research report on Tuesday, March 7th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $39.19.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.